ATH 1105
Alternative Names: ATH-1105Latest Information Update: 22 May 2025
At a glance
- Originator Athira Pharma
- Class Anti-inflammatories; Antidementias; Neuroprotectants; Small molecules
- Mechanism of Action Hepatocyte growth factor stimulants; Proto-oncogene protein c-met stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Amyotrophic lateral sclerosis
- Preclinical Frontotemporal dementia
Most Recent Events
- 13 May 2025 Adverse events and pharmacokinetics data from phase I trial in Amyotrophic lateral sclerosis (In volunteers) released by Athira Pharma
- 06 Dec 2024 Pharmacodynamics data from preclinical studies in Amyotrophic lateral sclerosis released by Athira Pharma
- 25 Nov 2024 Athira Pharma completes phase-I clinical trials in Amyotrophic lateral sclerosis (In volunteers) in USA (PO) (NCT06432647)